This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Ranked Momentum Stocks to Buy for March 24th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 24th
A New Strategist Game: Global Week Ahead
by John Blank
A swift global coronavirus pandemic opened up a new, nimble stock strategist game. How low can S&P 500 earnings go, and how cloudy can the outlook become?
Market is Wavering! Buy 5 Best Low-Volatility Stocks Now
by Tirthankar Chakraborty
Low-volatility stocks tend to hold up better in tough times. More interestingly, these stocks have done better over longer periods of time, even before the coronavirus-induced market crash.
Top Ranked Momentum Stocks to Buy for March 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 23rd.
Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus
by Ekta Bagri
Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
Pfizer's Eczema Drug & Pneumococcal Vaccine Succeed in Study
by Zacks Equity Research
Pfizer's (PFE) atopic dermatitis (eczema) candidate, abrocitinib, and pneumococcal conjugate vaccine candidate meet primary endpoints in their respective late-stage studies.
Roche to Evaluate Actemra for Severe COVID-19 Pneumonia
by Zacks Equity Research
Roche (RHHBY) works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.
5 Low-Beta Stocks to Tackle Coronavirus-Led Market Volatility
by Sreoshi Bera
The current volatility in equity market calls for investment in these five low-beta stocks.
Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?
by Ekta Bagri
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Regeneron (REGN) Stock Moves -1.36%: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed the most recent trading day at $485, moving -1.36% from the previous trading session.
Merck's Chronic Cough Candidate Achieves Goals in Phase III
by Zacks Equity Research
Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
Pfizer, Regeneron Give Update on Coronavirus Drug Development
by Kinjel Shah
Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.
Hopes of a COVID-19 Vaccine Buoy Drug Makers: 3 Solid Buys
by Tirthankar Chakraborty
Shares of Moderna soared higher after the company dosed a patient with a vaccine against the novel coronavirus in the Phase 1 study. This, calls for investing in companies racing to develop a vaccine against COVID-19
Wall Street Continues to Witness Extreme Volatility
by Zacks Equity Research
Wall Street Continues to Witness Extreme Volatility.
Crest of the Wave in Sight: Commercial Paper, Congress Bailout & More
by Mark Vickery
The cresting of the coronavirus wave has yet to even reach us, yet the magnitude of what's to come is now more enormous than most had been considering.
Regeneron Up on Identification of Antibodies for Coronavirus
by Zacks Equity Research
Regeneron (REGN) announces identification of antibodies from its VelocImmune mice for the treatment of coronavirus.
5 Stocks in the S&P 500 ETF Still Up YTD
by Sweta Killa
Though most stocks in the S&P 500 ETF portfolio are in red from the year-to-date look, there are a few that are standing tall in the ongoing market turmoil.
Why Regeneron (REGN) Stock Might be a Great Pick
by Zacks Equity Research
Regeneron (REGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Company News for Mar 18, 2020
by Zacks Equity Research
Companies In The News Are: PFE, BNTX, REGN, DNKN. TMO.
Abeona Treats First Patient in Pivotal Gene Therapy Study
by Zacks Equity Research
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss
by Zacks Equity Research
The FDA grants breakthrough therapy status to Eli Lilly's (LLY) oral JAK inhibitor, Olumiant (baricitinib) for potential treatment of alopecia areata, an autoimmune disorder leading to hair loss.